Brief: Rtw Biotech Opportunities Says Rocket Pharmaceuticals Aligns with FDA on RP-A501 Trial
14/09/2023 07:40
Sept 14 (Reuters) - RTW Biotech Opportunities Ltd
RTW.L :
* ROCKET PHARMACEUTICALS REACHES ALIGNMENT WITH FDA ON
PIVOTAL
PHASE 2 TRIAL DESIGN FOR RP-A501 IN DANON DISEASE
Source text for Eikon: ID:nRSN4384Ma
Further company coverage: RTW.L
((Reuters.Briefs@thomsonreuters.com;;))